Posted by Netch on October 28, 2009, at 8:01:02
In reply to Re: Triple Reuptake Inhibitors. When?, posted by hopefullynow on October 28, 2009, at 6:08:05
A couple of years. DOV Pharmaceutical has done Phase I and Phase II tests.
" DOV Pharmaceutical, Inc. is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. The Company has previously funded drug development programs that are now at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (which has completed a pilot Phase 2 clinical trial), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, for bicifadine, with Blue Note Pharmaceuticals, for DOV diltiazem and with Neurocrine Biosciences, or Neurocrine, for indiplon..
DOV 21,947, is a triple reuptake inhibitor (serotonin, norepinephrine and dopamine inhibitor), or TRI, with potential efficacy in the treatment of depression and obesity. DOV 102,677 is another TRI, with potential efficacy in the treatment of alcohol abuse.. "
poster:Netch
thread:922940
URL: http://www.dr-bob.org/babble/20091021/msgs/923059.html